|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hu B, El Hajj N, Sittler S, Lammert N,
Barnes R and Meloni-Ehrig A: Gastric cancer: Classification,
histology and application of molecular pathology. J Gastrointest
Oncol. 3:251–261. 2012.PubMed/NCBI
|
|
3
|
Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu
S, Cristescu R, Nebozhyn M, Gong L, Yue YG, et al: Genomic
landscape and genetic heterogeneity in gastric adenocarcinoma
revealed by whole-genome sequencing. Nat Commun. 5:54772014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Deng N, Goh LK, Wang H, Das K, Tao J, Tan
IB, Zhang S, Lee M, Wu J, Lim KH, et al: A comprehensive survey of
genomic alterations in gastric cancer reveals systematic patterns
of molecular exclusivity and co-occurrence among distinct
therapeutic targets. Gut. 61:673–684. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wong H and Yau T: Molecular targeted
therapies in advanced gastric cancer: Does tumor histology matter?
Therap Adv Gastroenterol. 6:15–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim Y and Yeung ES: DNA sequencing with
pulsed-field capillary electrophoresis in poly(ethylene oxide)
matrix. Electrophoresis. 18:2901–2908. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bar-Eli M, Ahuja H, Gonzalez-Cadavid N,
Foti A and Cline MJ: Analysis of N-RAS exon-1 mutations in
myelodysplastic syndromes by polymerase chain reaction and direct
sequencing. Blood. 73:281–283. 1989.PubMed/NCBI
|
|
10
|
Collins SJ, Howard M, Andrews DF, Agura E
and Radich J: Rare occurrence of N-ras point mutations in
Philadelphia chromosome positive chronic myeloid leukemia. Blood.
73:1028–1032. 1989.PubMed/NCBI
|
|
11
|
Gentle A, Anastasopoulos F and McBrien NA:
High-resolution semi-quantitative real-time PCR without the use of
a standard curve. BioTechniques. 31:502, 504–506, 508. 2001.
View Article : Google Scholar
|
|
12
|
Schena M, Shalon D, Heller R, Chai A,
Brown PO and Davis RW: Parallel human genome analysis:
Microarray-based expression monitoring of 1000 genes. Proc Natl
Acad Sci USA. 93:10614–10619. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meyerson M, Gabriel S and Getz G: Advances
in understanding cancer genomes through second-generation
sequencing. Nat Rev Genet. 11:685–696. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Andrechek ER, Cardiff RD, Chang JT, Gatza
ML, Acharya CR, Potti A and Nevins JR: Genetic heterogeneity of
Myc-induced mammary tumors reflecting diverse phenotypes including
metastatic potential. Proc Natl Acad Sci USA. 106:16387–16392.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin Y, Wu Z, Guo W and Li J: Gene
mutations in gastric cancer: A review of recent next-generation
sequencing studies. Tumour Biol. 36:7385–7394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen K, Yang D, Li X, Sun B, Song F, Cao
W, Brat DJ, Gao Z, Li H, Liang H, et al: Mutational landscape of
gastric adenocarcinoma in Chinese: Implications for prognosis and
therapy. Proc Natl Acad Sci USA. 112:1107–1112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu Z, Huo X, Ye H, Tang C, Nandakumar V,
Lou F, Zhang D, Dong H, Sun H, Jiang S, et al: Genetic mutation
analysis of human gastric adenocarcinomas using ion torrent
sequencing platform. PLoS One. 9:e1004422014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nadauld LD and Ford JM: Molecular
profiling of gastric cancer: Toward personalized cancer medicine. J
Clin Oncol. 31:838–839. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ozaki T and Nakagawara A: p53: The
attractive tumor suppressor in the cancer research field. J Biomed
Biotechnol. 2011:6039252011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lane DP: Cancer. p53, guardian of the
genome. Nature. 358:15–16. 1992. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bellini MF, Cadamuro AC, Succi M, Proença
MA and Silva AE: Alterations of the TP53 gene in gastric and
esophageal carcinogenesis. J Biomed Biotechnol. 2012:8919612012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tahara T, Shibata T, Okamoto Y, Yamazaki
J, Kawamura T, Horiguchi N, Okubo M, Nakano N, Ishizuka T, Nagasaka
M, et al: Mutation spectrum of TP53 gene predicts
clinicopathological features and survival of gastric cancer.
Oncotarget. 7:42252–42260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ajani JA, D'Amico TA, Almhanna K, Bentrem
DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, et
al: Gastric cancer, version 3.2016, NCCN clinical practice
guidelines in oncology. J Natl Compr Cancer Netw. 14:1286–1312.
2016. View Article : Google Scholar
|
|
24
|
Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi
ST, Siu HC, Deng S, Chu KM, Law S, et al: Whole-genome sequencing
and comprehensive molecular profiling identify new driver mutations
in gastric cancer. Nat Genet. 46:573–582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li H and Durbin R: Fast and accurate short
read alignment with Burrows-Wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
1000 Genomes Project Consortium, ;
Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA,
Hurles ME and McVean GA: A map of human genome variation from
population-scale sequencing. Nature. 467:1061–1073. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cibulskis K, Lawrence MS, Carter SL,
Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES
and Getz G: Sensitive detection of somatic point mutations in
impure and heterogeneous cancer samples. Nat Biotechnol.
31:213–219. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
McKenna A, Hanna M, Banks E, Sivachenko A,
Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly
M and DePristo MA: The genome analysis toolkit: A mapreduce
framework for analyzing next-generation DNA sequencing data. Genome
Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang K, Li M and Hakonarson H: ANNOVAR:
Functional annotation of genetic variants from high-throughput
sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li J, Lupat R, Amarasinghe KC, Thompson
ER, Doyle MA, Ryland GL, Tothill RW, Halgamuge SK, Campbell IG and
Gorringe KL: CONTRA: Copy number analysis for targeted
resequencing. Bioinformatics. 28:1307–1313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lim BH, Soong R, Grieu F, Robbins PD,
House AK and Iacopetta BJ: p53 accumulation and mutation are
prognostic indicators of poor survival in human gastric carcinoma.
Int J Cancer. 69:200–204. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tatsuta M, Itoh T, Okuda S, Taniguchi H
and Tamura H: Effect of prolonged administration of gastrin on
experimental carcinogenesis in rat stomach induced by
N-methyl-N'-nitro-N-nitrosoguanidine. Cancer Res. 37:1808–1810.
1977.PubMed/NCBI
|
|
33
|
Lin SH, Li YH, Leung K, Huang CY and Wang
XR: Salt processed food and gastric cancer in a Chinese population.
Asian Pac J Cancer Prev. 15:5293–5298. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lane D and Levine A: p53 Research: The
past thirty years and the next thirty years. Cold Spring Harb
Perspect Biol. 2:a0008932010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oren M and Rotter V: Mutant p53
gain-of-function in cancer. Cold Spring Harb Perspect Biol.
2:a0011072010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bykov VJ, Issaeva N, Shilov A, Hultcrantz
M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G:
Restoration of the tumor suppressor function to mutant p53 by a
low-molecular-weight compound. Nat Med. 8:282–288. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bykov VJN, Issaeva N, Zache N, Shilov A,
Hultcrantz M, Bergman J, Selivanova G and Wiman KG: Reactivation of
mutant p53 and induction of apoptosis in human tumor cells by
maleimide analogs. J Biol Chem. 292:196072017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lambert JM, Gorzov P, Veprintsev DB,
Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman
KG and Bykov VJ: PRIMA-1 reactivates mutant p53 by covalent binding
to the core domain. Cancer Cell. 15:376–388. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zang ZJ, Cutcutache I, Poon SL, Zhang SL,
McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al:
Exome sequencing of gastric adenocarcinoma identifies recurrent
somatic mutations in cell adhesion and chromatin remodeling genes.
Nat Genet. 44:570–574. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang K, Kan J, Yuen ST, Shi ST, Chu KM,
Law S, Chan TL, Kan Z, Chan AS, Tsui WY, et al: Exome sequencing
identifies frequent mutation of ARID1A in molecular subtypes of
gastric cancer. Nat Genet. 43:1219–1223. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fenoglio-Preiser CM, Wang J, Stemmermann
GN and Noffsinger A: TP53 and gastric carcinoma: A review. Hum
Mutat. 21:258–270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ruthenburg AJ, Allis CD and Wysocka J:
Methylation of lysine 4 on histone H3: Intricacy of writing and
reading a single epigenetic mark. Mol Cell. 25:15–30. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Parsons DW, Li M, Zhang X, Jones S, Leary
RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, et al: The
genetic landscape of the childhood cancer medulloblastoma. Science.
331:435–439. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sjöblom T, Jones S, Wood LD, Parsons DW,
Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al:
The consensus coding sequences of human breast and colorectal
cancers. Science. 314:268–274. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huntsman DG, Chin SF, Muleris M, Batley
SJ, Collins VP, Wiedemann LM, Aparicio S and Caldas C: MLL2, the
second human homolog of the Drosophila trithorax gene, maps to
19q13.1 and is amplified in solid tumor cell lines. Oncogene.
18:7975–7984. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Je EM and Lee SH, Yoo NJ and Lee SH:
Mutational and expressional analysis of MLL genes in gastric and
colorectal cancers with microsatellite instability. Neoplasma.
60:188–195. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee J, Kim DH, Lee S, Yang QH, Lee DK, Lee
SK, Roeder RG and Lee JW: A tumor suppressive coactivator complex
of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase
MLL3 or its paralogue MLL4. Proc Natl Acad Sci USA. 106:8513–8518.
2009. View Article : Google Scholar : PubMed/NCBI
|
